TrialDiabetes, obesity & metabolism2021

DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.

Yu Pei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.